Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Computer-based Prescription Opioid Abuse Prevention for Adolescents

    SBC: HEALTHSIM, INC.            Topic: R42

    DESCRIPTION provided by applicant Recreational use of prescription opioids among adolescents is a significant and growing public health concern and has been referred to as an emerging epidemic in the U S Although a number of science based interactive drug abuse prevention programs exist focused on preventing use of non prescription drugs among youth to our knowledge no science based inter ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Cancer is the second leading cause of death after heart disease in the US Chemotherapy is a mainstay of treatment after surgical removal of tumors but the balance of clinical benefit versus disabling or life threatening side effects is often uncertain Genotyping of cancers to identify mutated oncogenes has enabled an era of targeted therapy Drugs targeting ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent

    SBC: PHOTOLITEC LLC            Topic: 102

    DESCRIPTION provided by applicant Photolitecandapos s patented technology is focused on developing improved agents for tumor imaging image guided surgery and or photodynamic therapy PDT The proposed STTR proposal includes fluorescence image guided PDT a andquot See and Treatandquot approach The fluorescence imaging compound with long wavelength absorption near nm should be extremel ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD, LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Brain penetrant Hsp90 inhibitors for Alzheimer's disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION provided by applicant Neurodegeneration in Alzheimerandapos s disease AD may result from deposition of A as plaques in brain tissue However less effort has been made to elucidate the role of tau containing neurofibrillary tangles NFTs in AD Accumulating evidence suggests that tau containing NFTs is an important component in the initiation and progression of AD and other neu ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government